{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:54:10Z","timestamp":1791161650727,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003376.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000}}],"reference-count":86,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003376.pub3","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T01:11:33Z","timestamp":1202260293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","author":[{"given":"George A","family":"Wells","sequence":"first","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cranney","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Division of Rheumatology; 1053 Carling Ave Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Ottawa Civic Hospital \/ Loeb Research Institute; Clinical Epidemiology Unit; 1053 Carling Avenue Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boucher","sequence":"additional","affiliation":[{"name":"HTA Development Canadian Agency for Drugs and Technologies in Health (CADTH); 865 Carling Ave Suite 600 Ottawa Ontario Canada K1S 5S8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Welch","sequence":"additional","affiliation":[{"name":"University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street, Room 206 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[{"name":"Ottawa Health Research Institute; Epidemiology and Community Medicine; 451 Smyth Rd. Ottawa Ontario Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0002-9343(97)00019-3","article-title":"The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study","volume":"103","author":"Herd","year":"1997","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD003376.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjmed.2004.05.019","article-title":"Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study","volume":"117","author":"Ishida","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02242451","article-title":"The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study","volume":"16","author":"Lyritis","year":"1997","journal-title":"Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub3-BIB0004|cit4","first-page":"2784","article-title":"Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) [see comment] [erratum appears in J Clin Endocrinol Metab 1997 Nov;82(11):3740]","volume":"82","author":"Meunier","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01623461","article-title":"The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment","volume":"7","author":"Montessori","year":"1997","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/jcem-66-4-747","article-title":"Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study","volume":"66","author":"Pacifici","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01622291","article-title":"Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy","volume":"7","author":"Pouilles","year":"1997","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s007760100060","article-title":"Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis","volume":"6","author":"Shiota","year":"2001","journal-title":"Journal of Orthopaedic Science"},{"issue":"18","key":"10.1002\/14651858.CD003376.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis [see comment]","volume":"322","author":"Storm","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]","volume":"323","author":"Watts","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]","volume":"323","author":"Watts","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]","volume":"323","author":"Watts","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis","volume":"104","author":"Wimalawansa","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF03343728","article-title":"Prevention of early postmenopausal bone loss with cyclical etidronate","volume":"23","author":"Adami","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02405341","article-title":"Preliminary observations of a form of coherence therapy for osteoporosis","volume":"36","author":"Anderson","year":"1984","journal-title":"Calcified Tissue International"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0016|cit16","first-page":"159","article-title":"Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women","volume":"52","author":"Bolanca","year":"1998","journal-title":"Acta Medica Croatica"},{"issue":"10","key":"10.1002\/14651858.CD003376.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1139\/y02-126","article-title":"The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women","volume":"80","author":"Chilibeck","year":"2002","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1297-319X(01)00297-4","article-title":"Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy","volume":"68","author":"Cortet","year":"2001","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01623376","article-title":"The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women","volume":"3","author":"Evans","year":"1993","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S8756-3282(00)00303-3","article-title":"Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial","volume":"27","author":"Guanabens","year":"2000","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002239900291","article-title":"Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study","volume":"61","author":"Gurlek","year":"1997","journal-title":"Calcified Tissue International"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy [see comment]","volume":"95","author":"Harris","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cpt1976205593","article-title":"Etidronate disodium in postmenopausal osteoporosis","volume":"20","author":"Heaney","year":"1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/JCD:3:1:027","article-title":"The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study","volume":"3","author":"Heath","year":"2000","journal-title":"Journal of Clinical Densitometry"},{"issue":"19","key":"10.1002\/14651858.CD003376.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/BF01738113","article-title":"Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study 1. osteoporosis trial Hannover","volume":"66","author":"Hesch","year":"1988","journal-title":"Klinische Wochenschrift"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub3-BIB0026|cit26","first-page":"945","article-title":"Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis [Review] [34 refs]","volume":"155","author":"Hodsman","year":"1996","journal-title":"CMAJ: Canadian Medical Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002230001204","article-title":"Response of cortical bone to antiresorptive treatment","volume":"68","author":"Hyldstrup","year":"2001","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s007760100002","article-title":"Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate","volume":"6 (6)","author":"Iwamoto","year":"2001","journal-title":"Journal of Orthopaedic Science"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00002060-200206000-00010","article-title":"Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women","volume":"81","author":"Iwamoto","year":"2002","journal-title":"American Journal of Physical Medicine & Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2302\/kjm.52.113","article-title":"Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis","volume":"52","author":"Iwamoto","year":"2003","journal-title":"Keio Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00776-003-0655-5","article-title":"Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis","volume":"8","author":"Iwamoto","year":"2003","journal-title":"Journal of Orthopaedic Science"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0032|cit32","first-page":"574","article-title":"The treatment of osteoporosis with disodium ethane-1,1-diphosphonate","volume":"78","author":"Jowsey","year":"1971","journal-title":"Journal of Laboratory and Clinical Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jbmr.5650040203","article-title":"Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate","volume":"4","author":"Mallette","year":"1989","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.57.6.346","article-title":"Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women","volume":"57","author":"Masud","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","article-title":"Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment [erratum appears in Am J Med 1998 Jun;104(6):608]","volume":"103","author":"Miller","year":"1997","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00404-002-0340-5","article-title":"Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT","volume":"268","author":"Morishige","year":"2003","journal-title":"Archives of Gynecology & Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2265.1994.tb02537.x","article-title":"Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation","volume":"41","author":"Orme","year":"1994","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0039|cit39","first-page":"968","article-title":"Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis","volume":"78","author":"Ott","year":"1994","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/BF02242942","article-title":"Clinical experience with etidronate in osteoporosis","volume":"13","author":"Ryan","year":"1994","journal-title":"Clinical Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF02556464","article-title":"Effect of etidronate disodium on bone turnover following surgical menopause","volume":"44","author":"Smith","year":"1989","journal-title":"Calcified Tissue International"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","article-title":"The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime","volume":"12","author":"Steiniche","year":"1991","journal-title":"Bone"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub3-BIB0043|cit43","first-page":"1560","article-title":"Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis","volume":"23","author":"Storm","year":"1996","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0044|cit44","first-page":"85","article-title":"[Treatment of postmenopausal osteoporosis with etidronate] [Italian]","volume":"90","author":"Terranova","year":"1999","journal-title":"Minerva Medica"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(99)80102-8","article-title":"Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study","volume":"99","author":"Wimalawansa","year":"1995","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0046|cit46","unstructured":"Black D Use of T-Scores to establish comparable diagnostic categories for bone densitiometers [abstract] NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis and Therapy Bethesda (MD)"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporosis International"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003376.pub3-BIB0049|cit49","first-page":"1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"issue":"14","key":"10.1002\/14651858.CD003376.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0051|cit51","article-title":"Canadian Adverse drug Reaction Monitoring Program. Etidronate","volume-title":"Adverse reaction database","author":"Health Canada","year":"2005"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0052|cit52","unstructured":"Coyle D Hadj Tahar A Murphy G Perras C Skidmore B Boucher M Husereau D Teriparatide and Bisphosphonates of Treatment of Osteoporosis In Women: A Clinical and Economic analysis Canadian Agency for Drugs and Technologies in Health 2006"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01622285","article-title":"Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials","volume":"7","author":"Cardona","year":"1997","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0054|cit54","unstructured":"Cates C Visual Rx NNT Calculator 2.0 2004"},{"issue":"7","key":"10.1002\/14651858.CD003376.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporosis International"},{"issue":"9","key":"10.1002\/14651858.CD003376.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"American Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s001980170147","article-title":"A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis","volume":"12","author":"Cranney","year":"2001","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0058|cit58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003376","article-title":"Etidronate for treating and preventing postmenopausal osteoporosis","author":"Cranney","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"6964","key":"10.1002\/14651858.CD003376.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"4","key":"10.1002\/14651858.CD003376.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jbmr.5650070413","article-title":"Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group","volume":"7","author":"Ettinger","year":"1992","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD003376.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Annals of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003376.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0067|cit67","first-page":"637","article-title":"Osteoporosis","volume-title":"Therapeutic Choices","author":"Hanley","year":"2003"},{"issue":"14","key":"10.1002\/14651858.CD003376.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0069|cit69","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub3-BIB0070|cit70","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"CMAJ"},{"issue":"8","key":"10.1002\/14651858.CD003376.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD003376.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00002018-200225110-00003","article-title":"Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review","volume":"25","author":"Kherani","year":"2002","journal-title":"Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0074|cit74","unstructured":"Alendronate and vertebral fracture risk [multiple letters] Mayo Clinical Proceedings 2005 1233 41"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group [see comment]","volume":"344","author":"McClung","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0076|cit76","unstructured":"Health Canada Medeffect [website] Health Canada 2005"},{"issue":"5","key":"10.1002\/14651858.CD003376.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/oxfordjournals.aje.a115204","article-title":"Epidemiology of vertebral fractures in women","volume":"129","author":"Melton","year":"1989","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD003376.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Diagnosis","year":"2001","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1002\/14651858.CD003376.pub3-BIB0079|cit79","first-page":"262","article-title":"The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract]","volume":"14","author":"Okeksik","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD003376.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0895-4356(94)90004-3","article-title":"Pain and disability associated with new vertebral fractures and other spinal conditions","volume":"47","author":"Ross","year":"1994","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD003376.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0895-4356(03)00110-0","article-title":"Should meta-analysts search Embase in addition to Medline?","volume":"56","author":"Sampson","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0082|cit82","unstructured":"Shukla V Treating osteoporosis with teriparatide: many unknowns? Issues in Emerging Health Technologies 2003"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003376.pub3-BIB0083|cit83","first-page":"159","article-title":"The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract]","volume":"14","author":"Silverman","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0084|cit84","volume-title":"Evidence-based Rheumatology","author":"Tugwell","year":"2004"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0085|cit85","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group","volume":"843","year":"1994","journal-title":"World Health Organization Technical Report Series"},{"key":"10.1002\/14651858.CD003376.pub3-BIB0086|cit86","unstructured":"Wells GA Cranney A Bouchere M Peterson J Shea B Robinson V Coyle D Tugwell P Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69] Ottawa: Canadian Agency for Drugs and Technologies in Health 2006"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003376.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003376.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:24:04Z","timestamp":1630668244000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003376.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":86,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003376.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003376.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}